HLB Therapeutics Co Ltd
115450
Company Profile
Business description
HLB Therapeutics Co Ltd is a biotech company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a biopharmaceutical company focused on alleviating patient suffering.
Contact
22F, Parkview Tower
6, Jeongja-Dong, Bundang-Gu
Seongnam-si463-811
KORT: +82 317867800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
95
Stocks News & Analysis
stocks
Unconventional wisdom: Should I sell this underperforming ASX share?
Going back to my original thesis to evaluate a position.
stocks
Wildly overvalued ASX stock is skating on thin ice
This company dominates its industry and could be flirting with regulatory intervention.
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,076.60 | 25.40 | -0.28% |
| CAC 40 | 7,743.00 | 33.68 | 0.44% |
| DAX 40 | 24,162.86 | 29.64 | -0.12% |
| Dow JONES (US) | 44,175.61 | 206.97 | 0.47% |
| FTSE 100 | 9,095.73 | 5.04 | -0.06% |
| HKSE | 24,858.82 | 222.81 | -0.89% |
| NASDAQ | 21,450.02 | 207.32 | 0.98% |
| Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
| NZX 50 Index | 12,844.63 | 42.47 | -0.33% |
| S&P 500 | 6,389.45 | 49.45 | 0.78% |
| S&P/ASX 200 | 8,807.10 | 24.30 | -0.28% |
| SSE Composite Index | 3,635.13 | 4.54 | -0.12% |